Posted by Michael Wonder on 25 Oct 2021
COVID-19: EMA starts rolling review of molnupiravir
25 October 2021 - EMA’s CHMP has started a rolling review of the oral antiviral medicine molnupiravir (MK 4482; Lagevrio), developed by Merck Sharp & Dohme in collaboration with Ridgeback Biotherapeutics for the treatment of COVID-19 in adults.
The CHMP’s decision to start the rolling review is based on preliminary results from laboratory (non-clinical data) and clinical studies.
